USING DATA TO OPTIMIZE SAFE PATIENT CARE

TPP Alberta has been monitoring the use of prescription drugs prone to misuse and abuse since 1986.Â

When prescribing and dispensing data meet certain criteria, we alert physicians and others involved in the care of the patient. We provide those involved with information and direct them to helpful resources.


Drugs we are monitoring

Includes Type 1 and Type 2 medications.

Information for Prescribers

Registering as a prescriber with TPP Alberta

  • Prescribers must register with TPP Alberta to prescribe any medication on the TPP medications list.
  • Medical Residents must obtain approval from their program director prior to registering with TPP Alberta.
Registration form for PrescribersRegistration form for Medical Residents

Re-ordering Secure TPP pads

Email TPPinfo@cpsa.ab.ca or contact 1-800 561-3899 ext 4939. Include the following information with your request:

  1. Your registration number
  2. Your clinic’s complete address including postal code
  3. Phone number that is to be printed on the pads
  4. Complete address for shipping, if different.

Lost or stolen forms or pads

If your TPP pad or any of the forms are missing or stolen, you must contact the police and notify TPP Alberta immediately. The prescriber should provide the following information to TPP Alberta:

  1. Date of theft or loss
  2. Tracking number of the missing form(s) or pad(s)
  3. Name of the last patient prescribed a Type 1 prescription
  4. The police file number and investigating constable’s name and phone number

Information for Pharmacists

List of Stolen & Missing TPP Forms

Pharmacists looking for the list of stolen or missing TPP forms can access the list through the Alberta College of Pharmacists (login required) or contact TPP Alberta directly at TPPinfo@cpsa.ab.ca or call 1-800-561-3899 ext. 4939.

Prescribers with TPP Prescribing Restrictions

Based on data from TPP Alberta, the CPSA can impose prescribing conditions on physicians that restrict their prescriptive authority under certain situations. These listings and conditions are shown below:

SurnameGiven NameRestrictions
BeeharryRajRestricted from prescribing any benzodiazepines, including chloral hydrate, zopiclone and other z-drugs unless the prescription is: a. Prescribed as an anticonvulsant; b. Prescribed to a patient for a maximum of two weeks in any three month period; or c. Supported by written direction or recommendation from a consult from a specialist or knowledgeable colleague. Restricted from prescribing narcotic analgesics (or any products containing Codeine) unless the prescription is: a. A narcotic analgesic prescribed to a patient with malignancy-related pain that is documented by a pathology report or consultant’s report; b. A narcotic analgesic prescribed to a patient with acute, non-malignant pain for a maximum of two weeks for any three-month period; or c. Supported by written direction or recommendation from a consult from a specialist or knowledgeable colleague
CollettFranklin DeanPrescribing restrictions apply. Prescribing restrictions for the following medications: Triplicate Prescription Program medications, anabolic steroids, methylphenidate, barbiturates, codeine containing drugs, amphetamine or amphetamine like appetite suppressants, benzodiazepines and other anxiolytics, hypnotics and sedatives, and muscle relaxants.
DatarSunilShall not prescribe, dispense or provide samples of any drug that is listed on the College’s Triplicate Prescription Program Product List, whether prescribed using the triplicate pad or otherwise monitored by the program, inclusive of codeine products, benzodiazepines and “Z Class Drugs”.
GauriMohammed AliRestricted from prescribing triplicate prescriptions with the exception of opioid analgesics for malignancy-related pain documented by pathology report and/or consultant’s report.
IwashkiwBoris MichaelRestricted from prescribing any drugs on the Triplicate Prescription Program (and no products containing Codeine) or any benzodiazepines and other anxiolytics, hypnotics and sedatives including Chloral Hydrate, Zopiclone or other Z-Drugs.
Jabbari-ZadehShahramRestricted from prescribing tramadol containing medications, and any other medication on the Triplicate Prescription Program Medication List (Type 1 and Type 2 medications).
JackmanKevin F.M.Restricted from prescribing any benzodiazepines and other anxiolytics, hypnotics and sedatives including chloral hydrate, zopiclone and other z-drugs with the following exceptions: prescribed as an anticonvulsant. Restricted from prescribing any drugs on the Triplicate Prescription Program Product List (and no products containing Codeine or tramadol) with the following exceptions: Narcotic analgesics for patients with malignancy-related pain that is documented by a pathology report or consultant’s report and non-TPP Narcotic analgesics (Codeine or Tramadol) for patients with acute non-malignant pain for a maximum of one week for each patient in any three month period.
KrogPieterRestricted from obtaining or using a triplicate prescription pad.
KordybanMichaelVoluntarily surrenders all triplicate prescription pads under his control and shall not request resumption of prescribing of medications requiring the use of a triplicate prescription pad, in any manner.
LeivoRayRestricted from prescribing medications monitored by the Triplicate Prescription Program, or tramadol products, effective May 24, 2018
McAlpineBrian DouglasRestricted from prescribing triplicate medications.Restricted from prescribing stimulant medications or medications used in the treatment of Attention Deficit Disorder.
McDonaldNormanPrescribing restrictions apply. Not initiate to current patients prescriptions for benzodiazepines and other anxiolytics, hypnotics and sedatives including chloral hydrate, zopiclone and other z-drugs with the following exceptions: a. unless prescribed as an anticonvulsant; b. for a maximum period of two weeks for each patient in any three month period. Not initiate to current patients prescriptions for opioid analgesics, including Codeine with the following exceptions: a. for the management of cancer pain or palliative care; b. for a maximum of two weeks for each patient in any three month period.
McPeakBrian K.Restricted from prescribing medications which require a triplicate prescription pad.
MohamedAtaher SRestricted from prescribing any medication monitored by the Triplicate Prescription Program.
MoirJames AllanRestricted from prescribing medications designated as part of the Triplicate Prescription Program.
NeuS. RandallRestricted from prescribing triplicate medication.
RosenstockCarlRestricted from prescribing any benzodiazepines, including chloral hydrate, zopiclone and other z-drugs with the following exceptions: 1. Prescribed as an anticonvulsant; 2. Prescribed to a patient for a maximum of two weeks in any three month period; or 3. Supported by a direction or recommendation arising from a consult from a specialist or knowledgeable colleague. Restricted from prescribing any drugs on the Triplicate Prescription Program List (or any products containing Codeine) with the following exceptions: 1. A narcotic analgesic prescribed to a patient with malignancy-related pain that is documented by a pathology report or consultant’s report; 2. A narcotic analgesic prescribed to a patient with acute non-malignant pain for a maximum of two weeks for any three month period; or 3. Supported by a direction or recommendation arising from a consult from a specialist or knowledgeable colleague.
ShepsDavid M.Restricted from prescribing Tramadol and any medications on the Triplicate Prescription Program medications list.
SwartJohanRestricted from prescribing Tramadol products or medications on either of the schedules of the Triplicate Prescribing Program.
ThompsonRobert DouglasRestricted from prescribing any medications which require a Triplicate Prescription pad.
WhiteRoger TylerDiscontinue providing medications of potential abuse including triplicate program medications and benzodiazepines.
WorkunShane AlexTriplicate prescriptions for in-patient hospital or long-term patient for a maximum of two weeks.
Pharmacists can contact TPP Alberta for guidance if questions arise or advice is required in specific circumstances at TPPinfo@cpsa.ab.ca or at 1-800-561-3899.

FAQs

Eligible prescribers (physicians, podiatric physicians, nurse practitioners, dentists and veterinarians) may apply to TPP Alberta by completing the Registration form for Prescribers or the Registration form for Medical Residents.

TPP Alberta Resources


WE CAN HELP

Contact TPP Alberta

1-800-561-3899 (in Canada) ext. 4939

TPPInfo@cpsa.ab.ca